HOME > BUSINESS
BUSINESS
- Entyvio’s SC Form Accepted by US FDA for Review: Takeda
May 13, 2019
- Sunovion’s Schizophrenia Agent Awarded US Breakthrough Therapy Designation
May 13, 2019
- Shionogi's FY2018 Sales Up 5.5% on HIV Royalties, Xofluza Notches 26.3 Billion Yen
May 10, 2019
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Eisai to Invest 15 Billion Yen to Excavate Innovative Technology; 1st Pact Signed with App Developer
May 10, 2019
- Takeda to Divest Dry Eye Drug to Novartis for US$5.3 Billion
May 9, 2019
- Japan Generic Makers Cutting Back on New Grad Hiring in Near-Saturated Market: Jiho Survey
May 9, 2019
- Kissei Braced for 65% Sales Fall for Urief on Generic Onslaught; Exec Admits Uphill Battle for Nesp Biosimilar
May 9, 2019
- Sumitomo Dainippon to Set Up Cell Therapy Hub in San Diego
May 9, 2019
- DS-8201 Delivers in PII Breast Cancer Study: Daiichi Sankyo/AZ
May 9, 2019
- Eisai Kicks Off Joint Program with UK Institution to Support Dementia Research
May 9, 2019
- Bioverativ Japan Now Merged into Sanofi
May 8, 2019
- Eisai, Purdue Wind Up Partnership for Insomnia Drug Lemborexant
May 8, 2019
- Shionogi, AI Startup Tie Up to Develop Influenza Diagnostic Device
May 8, 2019
- Japan Generic Market to Reach 1.2 Trillion Yen by 2022, Biosimilars, AG Market to Expand Too: Fuji Keizai
May 7, 2019
- Daiichi Sankyo Skips Pre-Verification for Vaccine Sterility Test, No Safety Concerns Found
May 7, 2019
- Boehringer Workforce Dwindles by 500 in Japan, MSD by 300: Jiho Survey
May 7, 2019
- Dupixent Now Available for Self-Injection
May 7, 2019
- Daiichi Sankyo Exercises Option to Commercialize Bispecific Antibodies Based on Joint Research with Zymeworks
May 7, 2019
- After Biogen Pullout, Salix Picks Up Rights to Mitsubishi Tanabe’s MT-1303
May 7, 2019
ページ
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
